JH gene sequence analysis in a patient with Waldenström’s macroglobulinaemia with subsequent development of immunoblastic lymphoma

H Kondo, N Yumoto, A Mikata, Y Date

Abstract
A case of Waldenström’s macroglobulinaemia with subsequent development of immunoblastic lymphoma in a 69-year-old man is reported. Plasmacytoid lymphocytes were initially observed in both peripheral blood and bone marrow smears. Lymph node biopsy was interpreted as malignant lymphoma, diffuse mixed cell type compatible with Waldenström’s macroglobulinaemia. Complete remission resulted on combined treatment with prednisolone and melphalan. Four years later, lymphadenopathy occurred and biopsy revealed the development of an immunoblastic lymphoma. Initially, this lymphoma was thought to be the malignant transformation of Waldenström’s macroglobulinaemia, because both tumours produced IgM (κ light chains). Sequencing of immunoglobulin heavy chain genes of Waldenström’s macroglobulinaemia and immunoblastic lymphoma cells, however, revealed different DH and JH usage between the two, indicating the independent nature of the two haematological malignancies. These results indicate that clonality of primary and secondary tumours should be determined not by phenotypic, but by genotypic analysis.

Case report
A 64-year-old man was admitted to hospital in May 1989 with hepatosplenomegaly and systemic lymphadenopathy. Haematological analysis on admission revealed anaemia and leucocytosis with a leucocyte count of 11·1×10⁹/l. Peripheral blood smears showed 60% lymphoplasmacytoid cells. Serum protein was 12·6 g/dl and immunoelectrophoresis demonstrated that the monoclonal protein was IgM (κ light chains) with a serum concentration of 19·590 mg/dl. The bone marrow was infiltrated by lymphoplasmacytoid cells. Microscopic examination of a lymph node revealed malignant lymphoma, mixed large and small plasmacytoid cells of B cell phenotype and mature plasma cells. A diagnosis of Waldenström’s macroglobulinaemia was reached. The patient was treated with melphalan and prednisolone for three and a half years. His general condition improved and the concentration of serum IgM decreased to within the normal range following treatment.

The patient was readmitted because of recurrent lymphadenopathy four years after the initial diagnosis. There were no abnormal haematological data except for slight anaemia.
Blood biochemistry disclosed an elevated lactate dehydrogenase activity (840 IU/l). Serum immunoelectrophoresis showed a trace amount of monoclonal IgM (k light chains) although its serum concentration was within normal range. Bone marrow studies disclosed a focal infiltration of lymphoplasmacytoid cells, although abnormal cells were not detected in peripheral blood. Immunoblastic lymphoma was detected on examination of a lymph node biopsy specimen taken from the neck. Waldenström’s macroglobulinaemia was thought to have developed into immunoblastic lymphoma and the patient was treated with the CHOP (cyclophosphamide, hydroxydaunomycin, vincristine, and prednisolone) regimen following partial remission, but died one and a half years later.

Surface markers of abnormal cells in the peripheral blood were stained by an indirect immunofluorescence method using CD20 (B1), SmIg and PCA-1 monoclonal antibodies and analysed using flow cytometry. Paraffin wax sections of bone marrow and lymph node biopsy specimens were stained by the Streptavidin-biotin peroxidase (ABC) method using CD20 (L26), CD45RO (UCHL-1), anti-IgM, anti-k, anti-l, MB-1, and MT-1 antibodies. DNA was extracted from the paraffin wax blocks and amplified according to Wan et al with minor modifications. Briefly, 1 μl extracted DNA was subjected to polymerase chain reaction (PCR) amplification with 2.5 units of Taq polymerase and with primers for V and J regions at a final concentration of 0.5 μM in 100 μl standard buffer. The denaturing step was carried out for 120 seconds at 94°C, the annealing step for 120 seconds at 60°C, and the extension step for 120 seconds at 72°C for 30 cycles using a thermal sequencer. The amplified DNA sample was diluted 1000-fold in water and added to a fresh PCR reaction mixture, followed by a second amplification sequence of 20 cycles. FR3A and LJH primers were used in the first 30 cycles, and FR3A and VLJH in the second 20.

For DNA sequencing, PCR products were subcloned into the PCRTM vector using Taq dye primer cycle sequencing kits (Applied Biosystem, Tokyo, Japan).

Results

PERIPHERAL BLOOD AND BONE MARROW

In the smears of peripheral blood taken during the initial hospitalisation no one abnormal cell predominated; there were medium-sized lymphoid cells with basophilic cytoplasm and irregularly shaped nuclei with delicate chromatin and distinct nucleoli. Other cells resembled mature plasmacytes, although some had irregularly shaped nuclei. Surface marker analysis disclosed that the abnormal cells were strongly positive for PCA-1, weakly positive for CD20 and negative for SmIg. In bone marrow specimens accumulation of both mature and immature plasmacytes was observed at both the initial (fig 1A) and second hospitalisation.

LYMPH NODES

The first lymph node biopsy showed extensive, but incomplete, obliteration of nodal architecture due to proliferation of medium to large atypical lymphoid cells. The large cells had round nuclei while the medium-sized cells were lymphoplasmacytoid in nature (fig 1B). Most proliferating cells in the lymph node showed positive cytoplasmic staining with antiserum to IgM k light chains and CD20. In 1993, the second lymph node biopsy specimen showed extensive and complete obliteration of the nodal architecture due to diffuse proliferation of immunoblasts (fig 2A). Some of
these cells were positive for anti-IgM κ, but not for λ, light chains (fig 2B). Positive staining was also observed for CD20 but not for CD45RO.

SEQUENCES OF IGH GENES OBTAINED BY PCR

Sequencing of PCR products revealed a particular rearrangement in both Waldenström's macroglobulinaemia and immunoblastic lymphoma node tissue. In Waldenström's macroglobulinaemia tumour clones the nucleotide sequence of the VDJ region was GCGAGC (VH), followed by a N insertion of AGTG,GCTGCTACT (D(DLA2)), by another N insertion of GGAGGACGC and by TTTTACTAC, which corresponds to JH4. The nucleotide sequence of immunoblastic lymphoma was as follows: GCGAGA (VH) followed by a N insertion of AGACATTGCTAC, by GTATTACTATGATAGTGTTA (D21-9), by another N insertion of CCGAGGT, and by GCTTTTGT (JH3).

Discussion

Transformation from a well differentiated to a less differentiated neoplasm is well recognised in lymphoproliferative diseases. Richter's syndrome refers to "reticulum cell sarcoma" which can develop in patients with chronic lymphocytic leukaemia (CLL). The relation between the primary and secondary neoplasms is unclear and controversial. Foon et al. studied the genetic relatedness between CLL and the more aggressive B cell malignancies and concluded that progression to more aggressive forms in patients with CLL can result from either clonal evolution or from an independent transforming event. Similar progression to large B cell lymphoma occurs in diffuse, small B cell lymphoma. There have been sporadic reports of Waldenström's macroglobulinaemia transforming to immunoblastic lymphoma, which occurs in 1-8% to 10-7% of patients, but only a few cases have been described in the literature preventing conclusions about the pathogenesis of these conditions to be drawn. The genetic relation between these two malignancies has not been studied to date. In the case presented here histological and immunophenotypic evidence suggested malignant transformation of a single tumour clone, but on analysis of PCR products these tumours were found to have different JH rearrangements indicating that in this patient Waldenström's macroglobulinaemia did not progress to immunoblastic lymphoma.

Cytotoxic drugs have been implicated in the genesis of secondary malignancies in various conditions. As treatment with alkylating agents has become more common, more cases of Waldenström's macroglobulinaemia developing signs of high grade lymphoma have been reported. Österberg and Rausing reviewed 20 cases of Waldenström's macroglobulinaemia which progressed to "reticulum cell sarcoma" and found that 10 of these patients had received alkylating agents. The time lapse between the start of therapy and death ranged from one and a half to eight years. Our patient developed a high grade lymphoma four years after achieving complete remission following prolonged medication with melphalan and prednisolone. The time interval was consistent with a post-chemotherapy lymphoma. Although in the paper by Österberg and Rausing only one patient had been treated with melphalan, that secondary malignancies often develop after treatment with this drug in cases of multiple myeloma suggests that it might be implicated in the generation of high grade malignant lymphomas. Other possibilities are that the immunodeficiency associated with Waldenström's macroglobulinaemia increases the risk of other malignancies by decreasing "immune surveillance", or that the initial abnormality that leads to the development of Waldenström's macroglobulinaemia also underlies the development of immunoblastic lymphoma. As Epstein–Barr virus is often implicated in the genesis of lymphoid malignancies in immunodeficient patients, the significance of infection in the development of secondary malignancies in Waldenström's macroglobulinaemia merits further study.

In patients whose primary neoplasm developed drug resistance, a malignant progression of this clone is likely to result in a secondary malignancy resistant to the same drug(s). However, if the secondary malignancy is a different clone, then it may be drug sensitive and respond well. Therefore, clonal examination, including analysis of immunoglobulin gene rearrangements, would have an immediate practical application in the routine diagnostic laboratory.


Jh gene sequence analysis in a patient with Waldenström's macroglobulinaemia with subsequent development of immunoblastic lymphoma

H Kondo, N Yumoto, A Mikata and Y Date

doi: 10.1136/mp.48.4.M215

Updated information and services can be found at:
http://mp.bmj.com/content/48/4/M215

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/